TheEdgeResearch
Home / Stocks / ZLDAF

Zelira Therapeutics Limited (ZLDAF)

OTC Healthcare Biotechnology
$0.20 ▲ +0.00%
Market Cap
$2.7M
Sector
Healthcare
Industry
Biotechnology
Beta
0.59
52-Wk Range
0.0089-0.4165
CEO
Oludare Odumosu
Country
AU
Currency
USD

Zelira Therapeutics Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Perth, WA, AU. The stock last traded at $0.20, up 0.00% on the session, giving a market capitalisation of $2.7M. On trailing twelve-month figures it carries a trailing P/E of -1.56, a net margin of -553029.3%. Its beta of 0.59 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-1.56
Price / Sales
10020.70
Price / Book
-1.29
EV / EBITDA
-2.15
Gross margin
-122400.2%
Operating margin
-602467.8%
Net margin
-553029.3%
Return on equity
—
Debt / equity
-0.48
Current ratio
0.11
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
8
IPO date
2017-03-07
Headquarters
Perth, WA, AU
About Zelira Therapeutics Limited

Zelira Therapeutics Limited (ZLD.AX) is an Australian biopharmaceutical firm dedicated to the research, development, and commercialization of cannabinoid-derived medicines for a variety of medical conditions. Its product portfolio includes HOPE™ brand formulations, which are available in Pennsylvania and Louisiana, as well as Zenivol™, a cannabinoid-based medication designed to treat chronic insomnia. In addition to its prescription offerings, the company provides several over-the-counter (OTC) products. These include SprinJene™ for oral hygiene and RAF FIVE™ for dermatological applications. Zelira also markets ITURA™, an advanced topical relief cream formulated to target multiple symptoms such as numbness, tingling, muscle cramps, insensitivity, and pain associated with Peripheral Artery Disease and diabetes. Zelira maintains key strategic partnerships with academic and medical institutions, including Curtin University, the Telethon Kids Institute, the University of Western Australia, St. Vincent's Hospital, and the Children's Hospital of Philadelphia. Originally incorporated in 2003 as Zelda Therapeutics Limited, the company rebranded to Zelira Therapeutics Limited in December 2019. Its corporate headquarters are located in Perth, Australia.

Comparable companies

Zelira Therapeutics Limited is most often compared with the following Healthcare names:

AGNPFAPLIFARUXFAXIMHAVLFPKTXRDDTFREPCFRNUGFSIGY
More research on ZLDAF
ZLDAF technical analysis ZLDAF TheEdge Score Compare against peers
Open full interactive analysis & DCF →